一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:IL7R Is Correlated With Immune Cell Infiltration in the Tumor Microenvironment of Lung Adenocarcinoma.
IL7R Is Correlated With Immune Cell Infiltration in the Tumor Microenvironment of Lung Adenocarcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肿瘤微环境在肺腺癌的发生、发展和预后中发挥重要作用。基于肺腺癌免疫微环境探索新的生物标志物,可有效预测预后并为临床治疗提供有效方案。
在本研究中,我们使用ESTIMATE算法对从TCGA数据库下载的肺腺癌数据中的免疫和基质成分进行评分。结果显示,免疫/基质评分与肺腺癌患者的临床特征和预后相关。白细胞介素-7受体(IL7R)是通过蛋白质-蛋白质相互作用网络交叉分析和Cox回归生存分析确定的重要预后生物标志物。根据TCGA和Oncomine数据库分析,IL7R在腺癌组织中的表达显著低于正常肺组织,并在临床组织样本中得到进一步验证。生存分析显示IL7R是肺腺癌的独立预后因素。IL7R表达与肺腺癌患者的总生存期和无进展生存期呈正相关,与肿瘤大小呈负相关。
我们的结果提示,IL7R通过调节肿瘤免疫微环境中免疫浸润细胞的比例来抑制肿瘤生长。IL7R可能成为肺腺癌患者有益的预后标志物,并在免疫治疗中具有巨大潜力。
Tumor microenvironment plays an important role in the development, progression, and prognosis of lung adenocarcinoma. Exploring new biomarkers based on the immune microenvironment of lung adenocarcinoma can effectively predict the prognosis and provide effective clinical treatment. In this study, we used the ESTIMATE algorithm to score the immune and stromal components in lung adenocarcinoma data downloaded from the TCGA database. The result showed that the immune/stromal score was associated with clinical features and prognosis of lung adenocarcinoma patients.
Interleukin-7 receptor (IL7R) is an important prognostic biomarker identified by intersection analysis of protein-protein interaction networks and Cox regression survival analysis. According to TCGA and Oncomine database analysis, IL7R expression in adenocarcinoma tissues was significantly lower than that in normal lung tissues and was further verified in clinical tissue samples.
Survival analysis showed IL7R was an independent prognostic factor of lung adenocarcinoma. IL7R expression was positively correlated with the overall survival and progression-free survival of lung adenocarcinoma patients and negatively correlated with tumor size.
Our results suggest that IL7R inhibits tumor growth by regulating the proportion of immune infiltrating cells in the tumor immune microenvironment. IL7R could be a beneficial prognostic marker in patients with lung adenocarcinoma and has great potential in immune therapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。